$4.46
0.10%
Nasdaq, Mon, Nov 25 2024
ISIN
US68232V3069
Symbol
ONTX
Sector
Industry

Onconova Therapeutics Inc. Stock price

$4.46
-0.50 9.99% 1M
-11.06 71.26% 6M
-14.18 76.07% YTD
-12.29 73.37% 1Y
-77.79 94.58% 3Y
-48.04 91.50% 5Y
-278,433.04 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.10%
ISIN
US68232V3069
Symbol
ONTX
Sector
Industry

Key metrics

Market capitalization $13.49m
Enterprise Value $8.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 35.13
P/S ratio (TTM) P/S ratio 58.65
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 0.00%
Revenue (TTM) Revenue $230.00k
EBIT (operating result TTM) EBIT $-24.09m
Free Cash Flow (TTM) Free Cash Flow $-30.18m
Cash position $5.41m
EPS (TTM) EPS $-141.35
P/E forward negative
P/S forward 58.65
EV/Sales forward 35.13
Short interest 0.10%
Show more

Is Onconova Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Onconova Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Onconova Therapeutics Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Onconova Therapeutics Inc.:

Buy
100%

Financial data from Onconova Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.23 0.23
0% 0%
100%
- Direct Costs 0.01 0.01
50% 50%
4%
0.21 0.21
0% 0%
91%
- Selling and Administrative Expenses 11 11
21% 21%
4,730%
- Research and Development Expense 13 13
5% 5%
5,830%
-24 -24
12% 12%
-10,470%
- Depreciation and Amortization 0.01 0.01
50% 50%
4%
EBIT (Operating Income) EBIT -24 -24
12% 12%
-10,476%
Net Profit -141 -141
598% 598%
-61,213%

In millions USD.

Don't miss a Thing! We will send you all news about Onconova Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Head office United States
CEO Werner Cautreels
Employees 17
Founded 1998
Website www.trawspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today